rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Valion Bio, Inc.

VBIO · Nasdaq

Health CareBiotechnologyNot moving yet

VBIO stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 91.4% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$57K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
11 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$55KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months2
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
Sheryle BoltonDirectorbought10,000at $1.0415 Apr 2026filed 20 Apr 2026
Christina Rizopoulos ValauriDirectorbought19,000at $0.94781 Apr 2026filed 2 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders11+3 on the quarter
New · exited4 · 1
Reported value$181K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Murchinson Ltd.new · filed 14 Aug 2026115,000$60K+115,000
CITADEL ADVISORS LLCnew · filed 14 Aug 202674,145$39K+74,145
Sanctuary Advisors, LLCunchanged · filed 13 Aug 202661,205$32K00.0%
Marex Group Ltdreduced · filed 14 Aug 202654,287$28K-4,976−8.4%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202619,374$10K-68,444−77.9%
UBS Group AGadded · filed 13 Aug 202611,094$5,769+8,728+368.9%
TWO SIGMA SECURITIES, LLCnew · filed 14 Aug 202610,162$5,283+10,162
Tower Research Capital LLC (TRC)added · filed 11 Aug 20262,095$1,089+1,511+258.7%
SBI Securities Co., Ltd.unchanged · filed 23 Jul 202616$800.0%
TD Waterhouse Canada Inc.new · filed 27 Jul 20265$2+5
31 Mar 2025 – 30 Jun 2026
2711Mar 25Jun 25Dec 25Mar 26Jun 26

News

Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestonehawaiitelegraph.com · 15 Oct 2026Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers ...pr-inside.com · 15 Oct 2026Valion Bio, Inc.: Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestonefinanznachrichten.de · 15 Oct 2026With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surgehawaiitelegraph.com · 14 Oct 2026Valion Bio, Inc.: With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surgefinanznachrichten.de · 14 Oct 2026Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New ...pr-inside.com · 9 Oct 2026Valion Bio, Inc.: Valion Bio: Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centersfinanznachrichten.de · 9 Oct 2026New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround ...pr-inside.com · 5 Oct 2026

Everyone who traded it

Dean Zikria Company insiderInterim CEO · last 22 Sep 20260 · 0
Lisa G. Wolf Company insiderCOO & CFO · last 18 Sep 20260 · 0
Michael K. Handley Company insiderChief Executive Officer · last 18 May 20260 · 0
Melinda Lackey Company insiderGeneral Counsel & SVP of Legal · last 1 May 20260 · 0
Sheryle Bolton Company insiderDirector · last 15 Apr 20261 · 0
Christina Rizopoulos Valauri Company insiderDirector · last 1 Apr 20261 · 0
Jennifer Ernst Company insiderChief Executive Officer · last 18 Dec 20250 · 0
Blake Gurfein Company insiderChief Scientific Officer · last 18 Dec 20240 · 0
Karen Drexler Company insiderDirector · last 9 Aug 20240 · 0
Kimberly Ann Bambach Company insiderInterim CFO · last 12 Mar 20240 · 0
Ryan Sabia Company insiderChief Operating Officer · last 8 May 20230 · 0
Veronica Cai Company insiderChief Financial Officer · last 1 Apr 20220 · 0

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-25.5%
Share count trendFY 2025 · to 17 Mar 202613.9%
Cash and equivalentsFY 2025 · to 31 Dec 2025$12.6M
Free cash flowFY 2025 · to 31 Dec 2025−$7.0M

Analyst forecasts

No analyst forecasts yet.